INTRODUCTION
Approximately twenty-five named mycoplasmas (belonging to the genera Mycoplasma, Acholeplasma and Ureaplasma) have been isolated from avian species. Mycoplasma gallisepticum and M. synoviae occur in chickens, turkeys and some other avian species. The turkey is the natural host of M. iowae, although it is also isolated Fabricant outlined three possible objectives for using M. gallisepticum vaccines (28) , namely: to provide protection against the following:
-respiratory tract disease -drops in egg production -transmission of M. gallisepticum through the egg.
A fourth objective, to facilitate the eradication of M. gallisepticum in multiple-age flocks by reducing the build-up of infectious reservoirs (104) , and/or by replacing endemic wild-type strains on a property with a milder, less readily transmissible vaccine variant, has also been suggested (70, 104) . Prevention of synovitis could be added to these same four objectives in the case of M. synoviae vaccines.
What is the ideal mycoplasma vaccine?
The ideal vaccine should be safe to use and consistently cost-effective. Safety is a more significant issue with living vaccines than with bacterins. However, animal welfare and food quality issues related to adjuvants used in bacterins are important concerns. Living vaccines should not cause disease in the vaccinated animal (an ideal not achieved by some widely used live avian virus vaccines) and should not inadvertently spread to, and certainly not cause disease in, neighbouring flocks. Attenuated strains should not revert to a virulent form. A marker which readily distinguishes the vaccine strain from wild types is a useful characteristic, as is a method of reliably assessing that an effective 'take' has occurred following vaccination.
The vaccine must be capable of stimulating solid lifelong protection, preferably from a single dose. It must be derived from properly defined seed stock, be of consistently high potency and purity and be cheap to manufacture using recognised and standardised practices. A long shelf life, without the necessity of special and expensive facilities for distribution and storage, is desirable, particularly for living vaccines. The vaccine should be convenient and cheap to administer to large numbers of birds. Improved flock performance resulting from the use of the vaccine must, of course, exceed the cost of purchase and administration. Each of the currently available vaccines has advantages and disadvantages and none attains the ideal status described above in every respect.
Mechanisms of immunity
Immune mechanisms operating in M. gallisepticum infections are not fully understood. It is possible that different mechanisms may operate for different routes of challenge and for resistance to infection compared with recovery from disease. The importance of immunoglobulin (Ig) has been demonstrated because bursectomised chickens have lower resistance to M. gallisepticum than normal chickens (5, 68) or thymectomised chickens (68) . However, a lack of correlation between levels of specific circulating antibody and protection has been well documented (68, 77, 100, 109) . It is likely that antibodies in the respiratory tract are important (8, 19, 23, 24, 116, 118) , with the predominant Ig class in respiratory secretions being IgG (8, 23, 116) . A protective role for cell-mediated immunity (CMI) has been discussed (2) , but the evidence for the significance of CMI is largely circumstantial.
As with M. gallisepticum, immunity to M. synoviae is bursal-dependent (67, 103) although protection is not correlated with level of serum antibody (91) . Antibodies in respiratory secretions may be more important (105) .
BACTERINS
M. gallisepticum bacterins are used commercially in several countries and contain inactivated organisms suspended in either aqueous oil emulsion (37) or aluminium hydroxide adjuvants (116) . Experimental use has also been made of bacterins combined with newer adjuvants, such as liposomes (9, 10) , iota carageenan (23, 24) and immune stimulating complex (99) . M. synoviae bacterins do not appear to be widely used in the poultry industry and there is little published information about them (90) .
Bacterins have the advantage that they are non-infectious and thus pose no risk of cross-infection to other stock or of reversion to virulence, both of which are potential problems with living vaccines. They are expensive to use, however, both in terms of requiring large amounts of antigen and the necessity of handling birds individually to administer the vaccine. Much of the published information on commercially available M. gallisepticum bacterins is about a product first described by Hildebrand et al. (37) .
Safety of oil emulsion bacterins
Oil emulsion bacterins are administered either by subcutaneous or intramuscular injection. The site of injection is important. Chickens vaccinated subcutaneously at the base of the skull developed a transient oedema around the eyes, whereas those vaccinated subcutaneously midway or lower in the nape of the neck showed no obvious adverse reaction (37) . Intramuscular injection into breast muscle is preferred, for reasons of ease of administration and fewer clinical complications, but this results in losses at processing (22) . Intramuscular injection into the upper leg is an alternative, but has resulted in a granulomatous cellulitus which was exacerbated by the movement of pullets from grower to layer houses (22) .
Efficacy of oil emulsion bacterins

Effects on respiratory disease and egg production
Experimental use of the product developed by Hildebrand and colleagues resulted in a reduced incidence of respiratory signs following artificial challenge and improved performance of layer flocks (36, 37) . A beneficial effect in the prevention of drops in egg production associated with M. gallisepticum was confirmed in experimental pen trial studies (33, 34) . In the four-week period after challenge, unvaccinated hens laid only about one half the number of eggs produced by once-or twice-vaccinated birds (33) .
Chickens vaccinated with a single dose at one week of age were protected against challenge with virulent M. gallisepticum seven weeks (36) or three weeks (40) later. However, other workers have demonstrated an age effect on the level of protective immunity elicited by bacterins. Chickens vaccinated at one day of age with a laboratory-prepared vaccine demonstrated little protection; those vaccinated at seven days old, variable protection; and those vaccinated at 11 days or older, significant protection (122) .
An effect caused by the number of doses has been noted in some (but not all) artificial challenge studies, with two doses providing superior protection to a single dose (30, 37) . In a field trial (37), twice-vaccinated pullets laid 12.8 eggs more per hen housed to 64 weeks than a control group vaccinated with F strain, whereas the difference was only 3.8 eggs in the case of a once-vaccinated group. Hen-housed egg production to 66 weeks of age was 7.6% to 9.1% higher in three commercial flocks which had been given two doses of bacterin during rearing than in unvaccinated controls (14) .
However, beneficial results have not always been obtained following the use of M. gallisepticum bacterins. No difference in egg production or mortality to 50 weeks of age was detected between commercial layers vaccinated at 19 weeks and unvaccinated hens, when both groups were placed into a multiple-age flock infected with M. gallisepticum (41) , while broiler breeders vaccinated at eight and 16 weeks showed only 'some protection' following natural challenge (31) . A vaccinated layer flock, which showed serological evidence of post-vaccinal exposure to M. gallisepticum, developed respiratory disease, increased mortality and a significant drop in egg production (15) . In recently published work, a bacterin was less effective than 125 ppm of tiamulin for three days per month in broiler breeders which were naturally challenged twelve weeks after vaccination (98) . Other products provided no protection in comparative studies with live vaccine strains (1, 113) . The reasons for these variable results obtained with bacterins are not clear but could be due to differences between bacterins, or to levels of challenge (60) or to the length of time between vaccination and challenge (36) .
Effect on the transmission of Mycoplasma gallisepticum through the egg
Vaccination with one or two doses of bacterin delayed the onset and reduced the rate of transmission of M. gallisepticum through the egg, in comparison with unvaccinated hens subsequently challenged by aerosol with virulent M. gallisepticum (33, 34) . However, vaccination was not effective when administered two weeks after experimental challenge (34) .
A tool to assist in the eradication of Mycoplasma gallisepticum
The subcutaneous administration of bacterin was reported to reduce the number of organisms in the trachea following challenge (37) . However, detailed quantitative studies showed that the mean number of M. gallisepticum isolated from the tracheas of bacterin-vaccinated chickens up to eight weeks after intra-tracheal challenge was only slightly less than that of unvaccinated controls (58) , while the infective dose 50% (ID 50 ) only increased from 10 2.9 organisms in unvaccinated controls to 10 3.7 organisms in chickens receiving two doses of bacterin (100). It was concluded that protection against respiratory infection elicited by parenteral administration of bacterin is limited and unlikely to be of practical significance (58, 100) . The results corroborated field observations that the continued use of M. gallisepticum bacterin on multiple-age poultry farms had failed to eliminate the infection (100).
Aluminium hydroxide-adsorbed bacterins
Chickens vaccinated with two intramuscular doses of an aluminium hydroxideadsorbed bacterin available in Japan showed fewer severe tracheal lesions and more rapid clearance of M. gallisepticum from the trachea than unvaccinated controls after experimental intra-tracheal challenge (117) . The best protection, however, occurred when the booster dose was administered without adjuvant by the intra-tracheal route (117, 118) .
Novel adjuvants
Problems with adverse tissue reactions and failure to stimulate an adequate local immune response following parenteral administration of oil emulsion adjuvants have prompted investigations of possible alternatives.
Bacterins containing liposomal adjuvants of differing size and charge stimulated a significantly greater CMI response (as measured by delayed-type hypersensitivity reaction) than oil emulsion bacterins (9) . However, this did not appear to be correlated with protection of the tracheal mucosa three days after challenge (9) . In subsequent studies, an M. gallisepticum bacterin in multilamellar positively charged liposome adjuvant stimulated a specific serum antibody response and resulted in improved egg production and a lower rate of egg transmission of M. gallisepticum than in unvaccinated hens challenged by air sac inoculation (12) . Similar results were obtained with an oil emulsion bacterin (12) .
An experimental M. gallisepticum bacterin containing 0.2% iota carrageenan adjuvant and administered by sequential intracoelomic and intrabursal routes increased levels of serum and local tracheal M. gallisepticum-specific
IgG, but not IgA or IgM, and provided significant protection against the development of air sac lesions following aerosol challenge (23) . In a comparative study of different routes of administration, intracoelomic inoculation followed by local respiratory tract administration were the most effective in protecting against airsacculitis (24) . The practicality of these routes of administering vaccines in commercial poultry production is questionable.
An immune stimulating complex (ISCOM) is a submicroscopic particle containing multimeric antigen within an adjuvant matrix based on Quillaja saponin, which is constructed to provide physically optimal presentation of antigen to the immune system. (82) . An experimental ISCOM vaccine prepared from detergent-solubilised M. gallisepticum cells provided significant protection against the development of lesions in chickens challenged by virulent M. gallisepticum injected into the air sac (99) . The vaccine was administered by a single intramuscular injection and produced none of the side effects observed with oil emulsion bacterins (99) . The protective response was antigen dose-dependent and occurred even though a specific serum antibody response was weak or absent, suggesting that a CMI response may be important in protection against direct air sac challenge with M. gallisepticum (99) .
Subunit vaccines
The rational development of effective subunit vaccines depends upon knowledge of the antigen(s) involved in protection, the nature of the protective immune response to the antigen(s) and an appropriate delivery system to stimulate an optimum protective immune response. There are gaps in the understanding of each of these, which may explain why there has been little experimental research on the development of subunit vaccines for avian mycoplasmas.
A subunit vaccine containing an electro-eluted 75 kDa putative adhesin protein (39) in liposomal adjuvant elicited an antibody response to that protein as well as cross-reactivity to 85 kDa and 56 kDa proteins of M. gallisepticum (11) . However, no attempt was made to measure the protective ability of this vaccine. It has been demonstrated that immunoglobulins in the respiratory tract of infected chickens inhibit attachment of M. gallisepticum in tracheal organ cultures (8) . Antibody to a 64 kDa protein of M. gallisepticum inhibited both growth and attachment of the organism in tracheal organ cultures (7) . Avakian and Ley have suggested the 64 kDa protein as a candidate for a subunit vaccine (7) . Whether a robust protective immunity to a complex organism such as M. gallisepticum can be elicited by a single antigenic component remains to be determined.
LIVE VACCINES
There are presently at least three living M. gallisepticum vaccines in commercial use in various parts of the world. These include the F strain, which is a naturally occurring strain of moderate virulence to chickens and high virulence to turkeys, and strains Intervet 6/85 and ts-11, which are artificially attenuated strains of low virulence. Strain MS-H is an attenuated strain of M. synoviae which is currently undergoing evaluation.
A live mycoplasma vaccine strain must multiply in the bird to an extent sufficient to stimulate long-term protective immunity but not sufficient to cause disease or to spread to other susceptible birds. This is a delicate balance, which is further complicated by the propensity of M. gallisepticum and M. synoviae to interact synergistically with other infectious agents and to produce more severe disease when birds are subjected to environmental and/or physiological stress. The virulence of an M. gallisepticum strain and the ability to stimulate a protective immune response are inversely related characteristics (3, 69, 73) . Completely avirulent strains do not appear to stimulate the immune system (69, 96) .
Origins of vaccine strains
While the origin of the F strain is not absolutely clear (42, 70, 71) , it is likely that it was originally isolated by Yamamoto and Adler in 1956 (119), who reported it to be pathogenic for chickens (120) and susceptible to antibiotics (119) . It was for these characteristics that it was chosen for investigations on immunisation in the 1960s by Luginbuhl et al. in Connecticut, the United States of America (USA) (78) . The F strain which has been used extensively in the field in the USA and in some other countries, is probably the same strain (70) .
The origins of the 6/85 strain have not been specifically stated in the Materials and Methods section of any published reference to its development. However, Evans et al. suggested that 6/85 was 'closely related' to the S6 strain on the basis of similarities in the deoxyribonucleic acid (DNA) restriction endonuclease cleavage patterns (although there were also obvious differences) (27) . Protein analysis revealed only a few differences between S6 and 6/85 and these were attributed to 'repeated in vitro passing during the development of the M. gallisepticum (6/85) strain' (27) .
The vaccine strain ts-11 was selected after the exposure of a low passage culture of an immunogenic Australian field isolate (strain 80083) of M. gallisepticum (97) to 100 µg/ml N-methyl-N-nitro-N-nitrosoguanidine (NTG) (110), a potent chemical mutagen. This strain was selected for its temperature-sensitive (ts + ) phenotype, which is manifested by an ability to grow well at 33°C but poorly at 39.5°C (110).
Strain MS-H was produced by NTG mutagenesis of an isolate of M. synoviae designated 86079/7NS, made from the choanal cleft of a layer chicken in Australia (84) . Like strain ts-11, MS-H was selected on the basis of a ts + phenotype (83) .
Methods of administration
F strain is usually administered by aerosol spray, but has also been given in drinking water or by intranasal instillation (70) . F strain has been used as fresh broth and thawed frozen or reconstituted lyophilised cultures, all of which gave satisfactory results in experimental challenge studies (76) . The concentration of viable organisms used in the field varies between 10 5.7 and 10 7.7 /ml (70) to 10 9 /ml (18) . Doses with titres as low as 10 5.5 viable organisms per ml are effective under experimental challenge conditions (76) . Pullets are usually vaccinated between 8 and 18 weeks of age, as vaccination later than 18 weeks is less effective (18) . Vaccination in the drinking water gave better results than vaccination by spray (18) . F strain was found to be sufficiently stable in a variety of diluents to allow this strain to be used in drinking water (57) .
The recommended route of administration for strain 6/85 is by aerosol spray (25), whereas ts-11 is administered by eye drop (109) . Dosage is important with both these attenuated strains. A dose of 10 4 organisms per bird of strain 6/85 was ineffective, whereas a dose of 10 7 organisms of a fresh culture provided significant protection (25) . The recommended eye drop dose of ts-11 is > 10 7.7 organisms (K.G. Whithear, unpublished findings). The efficacy of strain ts-11 in chickens subsequently challenged by aerosol infection diminished at doses < 10 6.7 organisms per bird (K.G. Whithear, unpublished findings). Protection against infraorbital sinus challenge was also dosedependent with a dose of about 10 7.7 organisms per bird required for optimal results (46, 53) .
Strain 6/85 is supplied as a lyophilised product, whereas ts-11 is currently distributed as a culture frozen at -70°C. The ts-11 vaccine has been used in the field in flocks from two weeks of age to 16 weeks (K.G. Whithear, unpublished findings).
Strain MS-H is administered and distributed in the same way as ts-11. In Australia, MS-H is commonly administered into the alternate eye at the same time as vaccination with ts-11 (94) .
Safety of Mycoplasma gallisepticum vaccines
Effects on the respiratory tract F strain caused air sac lesions when administered to one-day-old broilers by aerosol, particularly when given simultaneously with combined Newcastle disease virus (NDV) and infectious bronchitis virus (IBV) vaccine (93) . F strain is unsuitable for use in turkeys because it is too virulent (75) .
When administered by aerosol to chickens and turkeys, strain 6/85 caused mild to moderate air sac lesions in 20% to 30% of birds (25) . Strain ts-11 caused no lesions when inoculated in large doses into the thoracic air sacs of one-day-old chickens, whereas 90% of those inoculated with F strain developed moderate to severe lesions (49) . Similarly, no lesions were observed following air sac inoculation of two-weekold chickens and 28-week-old layer hens (110) . Eight-week-old chickens showed no respiratory signs or lesions when vaccinated by eye drop with 10 doses of ts-11, immediately following relocation by road transport, beak trimming and fowl pox vaccination. Day-old broilers exposed by aerosol to ts-11 in combination with IBV vaccine showed no air sac lesions up to three weeks later (110) . In a field trial involving 11,000 birds, ts-11 strain in combination with infectious laryngotracheitis (ILT) virus vaccine (strain ILTA 20 ) resulted in transient mild respiratory signs and conjunctivitis (F. Gordon and K.G. Whithear, unpublished findings). These were similar to signs observed in previous studies using ILTA 20 alone (F. Gordon, unpublished findings). Slight respiratory reactions were observed when strain ts-11 was administered to three-week-old chickens in combination with NDV/IBV vaccine (54) . By comparison, F strain caused moderate to severe respiratory reactions when used in combination with NDV/IBV vaccine (54) . Vaccination with ts-11 has been shown not to interfere with the efficacy of NDV vaccination (52) .
A detailed study using three different routes of inoculation demonstrated ts-11 to be virtually apathogenic for the turkey (110) . In a comparative study of virulence, 100% of one-day-old turkeys developed severe lesions and high mortality when F strain was inoculated into their air sacs, whereas 17% of those inoculated with ts-11 developed mild lesions (49) . F strain was also highly virulent when administered by coarse spray to one-day-old turkeys, with 100% showing upper respiratory tract lesions and 45% developing air sac lesions at 28 days of age (48) . No poults infected with ts-11 by coarse spray showed lesions at 28 days of age, although two developed a transient nasal exudate on the 7th day after infection (48) .
Effects on egg production and quality
Branton et al. (17) vaccinated 45-week-old pullets with high (114) passage F strain and found that egg production was significantly less (by 5.76% and 5.80% in two trials) but that various egg quality parameters were unaffected. The lowered production could not be attributed to any obvious effect on oviduct structure and function (16, 17) .
There was no significant difference in the percentage of eggs laid between unvaccinated birds and pullets vaccinated with strain 6/85 up to peak production, whereas a group vaccinated with F strain produced significantly fewer eggs over the same period (26) . When layer hens at peak production were inoculated directly into the abdominal air sacs with ts-11, egg production over the following seven weeks was not significantly different from that of uninfected controls (110) . By contrast, those inoculated with the unattenuated parent of ts-11 (strain 80083) laid significantly fewer (P<0.01) eggs (110) .
Other effects
Simmons and Branton cited anecdotal evidence that F strain may have contributed to increased heat stress mortality in hens (95) . This evidence was corroborated by subsequent experiments. The experiments showed that when hens housed in conventional sheds were subjected to high temperatures, those vaccinated with F strain had significantly higher rectal temperatures than unvaccinated controls (95) .
Transmissibility
The ideal vaccine strain should not be transmissible, either through the egg or horizontally to susceptible flocks. Hens vaccinated with F strain by eye drop while in lay showed no signs of egg transmission (34, 74) , although F-strain was isolated from 8/352 (2.27%) eggs laid in a seven-week period after aerosol vaccination. Lateral transmission of F strain between vaccinated birds and unvaccinated penmates occurred readily in the four weeks after vaccination, but thereafter became progressively slower, although it was still occurring as late as 27 weeks after vaccination (56) . While transmission to birds in an adjacent pen also occurred, no cross-infection was detected when groups of birds were separated by an aisle or empty pen (56).
Analysis of 11 M. gallisepticum field isolates made from unvaccinated flocks in Pennsylvania (32) , where F strain vaccine had been used for 30 years, supported a previous conclusion (56) of a relatively low level of F strain transmissibility. Only one of the 11 isolates was identified as F strain and this was obtained from a layer farm which had previously used the vaccine (32) . It was concluded that F strain was not an important cause of mycoplasmosis in Pennsylvania (32) . However, there is other documented field evidence that F strain is transmitted both within (78) and between sites (71). An M. gallisepticum outbreak in multiplier breeder flocks in North Carolina was conclusively shown to be caused by F strain and the possible source was identified as a commercial layer chicken flock in close proximity to the index case (71) . F strain has also been incriminated in a separate outbreak of mycoplasmosis in several meat turkey flocks (71) .
A recent comparison of the transmissibility of mild vaccine strains showed that 6/85 failed to be transmitted to susceptible chickens over a 15-week period of commingling, although difficulty was also experienced in reisolating the organism from the vaccinated birds (72) . Strain ts-11 was recovered from up to 40% of the commingled birds, but was not transmitted to chickens and turkeys separated from the vaccinated birds by a chainlink fence (72) . The relatively poor transmissibility of ts-11 has also been demonstrated in the field. No evidence of cross-infection occurred in 5,000 unvaccinated hens kept in the same house as, but separated by an aisle from, a similar number of vaccinated hens (114) .
No transmission through the egg was detected following direct administration of ts-11 into the abdominal air sacs in the region of the ovary (K.G. Whithear, unpublished findings). However, broiler breeders vaccinated twice by eye drop at 15 and 37 weeks of age were found to transmit M. gallisepticum between 44 and 51 weeks, although the possibility that this was the result of contamination of semen during artificial insemination could not be ruled out (K.G. Whithear, unpublished findings). In a subsequent experiment, no M. gallisepticum was isolated from 3,750 eggs laid by hens vaccinated with ts-11 by eye drop or exposed to the vaccinated hens by direct contact (K.G. Whithear, unpublished findings). No M. gallisepticum was isolated from the eggs or oviducts of hens vaccinated with ts-11 by eye drop at 22 weeks of age, whereas the organism was found in both eggs and oviducts of a group vaccinated with virulent R strain (55) . No evidence of egg transmission has occurred in the field, despite extensive use of ts-11 in broiler breeders in Australia over the past six years (K.G. Whithear, unpublished findings).
There appear to be no published studies to ascertain whether egg transmission of the 6/85 strain occurs.
Reversion to virulence
There is no published evidence to indicate that F strain has become more virulent over years of use. Aerosol exposure of chickens and turkeys, followed by reisolation of the organism from the trachea three days later, and repeating this procedure through nine further bird passages, has been used to assess the stability of strain 6/85 (25) . There were no significant differences between the back passaged and original vaccine in ability to cause air sac lesions (25) or in banding patterns, as demonstrated using DNA restriction endonuclease analysis (27) . The latter result was interpreted to indicate that 6/85 remains genetically stable in vivo, although phenotypic differences were apparent after bird passage as a quantitative increase in an 85 kDa protein (27) .
Two attempts have been made to serially passage ts-11 in birds without an intermediate in vitro culture step. However, it has not proven possible to achieve more than three in vivo back passages before the organism apparently disappears (110; K.G. Whithear, unpublished findings). After three bird passages (including an intermediate in vitro culture step), strain ts-11 retained the ts + phenotype and lack of pathogenicity (110) . In another study, which used an intermediate culture step, it was not possible to reisolate ts-11 from the nasal sinuses of birds infected at the fifth back passage, and the same birds remained susceptible to subsequent infection with virulent R strain (45) .
The ts + phenotype and attenuation
The selection criterion for identifying a ts + mutant is a back mutation rate of > 10-2 (88) . The back mutation rate of the ts-11 strain from a ts + to a ts-phenotype is in the order of . This would still be an unacceptably high level of back mutation if the vaccine strain relied solely on ts + phenotype for its attenuation. However, ts~ clones derived from the ts-11 vaccine strain were non-virulent, demonstrating that there is additional genomic change which accounts for this lack of virulence (K.G. Whithear, unpublished findings). This was borne out by analysis of two isolates made 3 weeks and 62 weeks after field vaccination with ts-11. Both isolates had the DNA restriction endonuclease banding profile of ts-11 (shared with the parent strain of ts-11, 80083) (108). The isolate made 3 weeks after vaccination expressed the ts + phenotype and was avirulent (like ts-11), whereas the isolate made 62 weeks after vaccination had a ts~ phenotype and was intermediate in virulence between ts-11 and the parent strain, 80083 (108) . That several genomic changes are involved in the attenuation of ts-11 is consistent with the fact that the chemical mutagen used to produce this strain causes multiple linked mutations. The alterations in the genome of ts-11 which account for the lack of virulence of this strain are at present unknown.
Efficacy of Mycoplasma gallisepticum vaccines
Preventing respiratory disease
One-day-old chicks vaccinated by eye drop with F strain were protected against subsequent experimental challenge (73, 92) . This is an interesting result because weakly virulent strains are ineffective or less effective when administered by eye drop to one-day-old chicks (73), as are parenterally administered bacterins (122) . The effectiveness of F strain vaccination of one-day-old broilers was not diminished in the presence of materaal antibody (77). Significant (P < 0.05) protection against development of air sac lesions was demonstrated when two-week-old chickens were vaccinated with strain 6/85 by aerosol and subsequently challenged 4 or 12 weeks later with virulent M. gallisepticum (25) . Both fresh (10 7 organisms/dose) and reconstituted lyophilised (10 8 organisms/ dose) vaccines were effective (25) .
In extensive laboratory studies with the ts-11 strain, vaccinated chickens have been better able to resist challenge with virulent M. gallisepticum administered by direct air sac inoculation (109), infectious aerosol (109) or intra-tracheal inoculation (K.G. Whithear and K. Harrigan, unpublished findings). Protection against respiratory signs persists up to at least 40 weeks after vaccination (Table I) (111, 113) , and was significantly greater than the protective immunity elicited by an Australian manufactured bacterin (113) . It is of interest that in experimental challenge studies, the ts-11 strain almost invariably provides solid protection against the development of tracheal (Fig. 1) and nasal sinus lesions but protection against the development of air sac lesions is less consistent (111) . It is possible that a different immune mechanism, possibly CMI, may be operating in regard to the air sacs, whereas immunoglobulins in respiratory secretions are important in preventing tracheal lesions. Perhaps ts-11 is less efficient at stimulating a consistent CMI response than the more virulent F strain. Both the dose of vaccine (as described above under 'Methods of administration') and the age of the chicken are crucial for successful vaccination with ts-11. Day-old broilers vaccinated by coarse spray were fully susceptible when challenged by aerosol with virulent M. gallisepticum three weeks later (109) , and chickens vaccinated at one day, 7 days or 14 days of age were susceptible to nasal sinus challenge (51) . Numerous other studies have shown that vaccinating at > 3 weeks of age elicits solid protective immunity.
A comparative study by Abd-El-Motelib and Kleven (1) showed that F strain provided superior protection against the development of air sac lesions following aerosol challenge to that of the milder vaccine strains 6/85 and ts-11. However, using inoculation into the infraorbital sinuses as a method of challenge, ts-11 gave superior protection in pen (46, 47, 50) and field (38) trials to both F and 6/85 strains. 
Preventing drops in egg production
The effectiveness of F strain in reducing drops in egg production associated with M. gallisepticum infection has been demonstrated in both pen (33) and fîeld trials (18, 21, 81) . In a two-year survey of 132 flocks, layer hens vaccinated with F strain (18) laid on average 7.0 (range 5.5 to 14.8) more eggs per hen housed over a 45-week production period than naturally infected birds. However, M. gallisepticum-free stock produced 8.7 (range 6.1 to 13.7) more eggs than the vaccinated birds over the same period (18) . There were no differences between layer strains (18). Mohammed et al. studied the impact of M. gallisepticum infection of layer flocks over two cycles of production, using a multivariable analysis to control for the impact of compounding factors (81) . Vaccinated flocks produced six more eggs per hen than unvaccinated M. gallisepticum-infected hens in the first cycle, but there was no difference in the second cycle (81) . However, it was again shown that M. gallisepticum-negative flocks produced the best performance (81) . In a controlled field trial, the hen day production of F strain vaccinated layers (21) was 3.5% greater than that of comparable unvaccinated birds, which were naturally infected on introduction to the layer house. There were no differences in mortality or egg quality between the two groups (21).
Evans et al. developed a mathematical model for assessing the effect of vaccines on preventing drops in egg production under conditions which simulated current husbandry practices (26) . Hens vaccinated with strain 6/85 produced significantly fewer (P < 0.05) eggs than those vaccinated with F strain in the periods immediately after challenge (i.e. deterioration and early recovery phases), but significantly more (P < 0.05) in the late recovery phase (26) .
Pullets vaccinated with ts-11 produced 41.3 eggs over a seven-week period after air sac inoculation with virulent M. gallisepticum, compared with 25.8 eggs (P < 0.01) produced by unvaccinated hens (109) . There was no significant difference in the number of eggs laid by vaccinated hens after challenge and those laid by a group of unchallenged controls (109) . In six field trials conducted prior to the commercial introduction of ts-11 into Australia, the mean production of vaccinated flocks was 219.6 eggs per hen housed to 65 weeks of age, compared with 211.9 eggs for unvaccinated groups (P < 0.01) (114) .
Preventing transmission through the egg
Vaccination with F strain significantly reduced the rate of and delayed, but did not eliminate, egg transmission of M. gallisepticum in hens challenged by aerosol (33) . Similarly, ts-11 strain reduced but did not prevent egg transmission in hens challenged by direct inoculation of virulent M. gallisepticum into the abdominal air sacs (K.G. Whithear, unpublished findings). However, ts-11 has been used extensively in breeder flocks in Australia and anecdotal evidence indicates that this strain has provided an effective alternative for the control of M. gallisepticum in situations where it is difficult to prevent the introduction of wild-type M. gallisepticum. Indeed, it has been the experience of some veterinarians that M. gallisepticum infection of broilers has ceased to be a problem following the use of ts-11 on multiple-age parent breeder farms (P.C. Scott, personal communication).
Displacement and eradication
The improved performance of M. gallisepticum-free flocks over M. gallisepticuminfected flocks, whether vaccinated or not, is indisputable. The wisdom of striving for the eradication of M. gallisepticum (and M. synoviae) from all flocks is embedded in the psyche of a generation of poultry veterinarians and producers and is officially sanctioned in policies such as those of the National Poultry Improvement Plan in the USA (6). It is not surprising, therefore, that the major role for vaccines in mycoplasma control is seen by many as their potential usefulness as tools to assist in the eradication of M. gallisepticum (and M. synoviae) from multiple-age flock sites (70) .
Bacterins have been tried unsuccessfully in this role (64) . Levisohn and Kleven argued that continued use of F strain on multiple-age sites may, over time, lead to the displacement of endemic field strain(s) (70) . Evidence to support such a hypothesis was obtained by Luginbuhl et al. (78) , who vaccinated chickens with F strain and then challenged them ten weeks later with the same strain. No M. gallisepticum could be isolated from the tracheas of the vaccinated birds one week after challenge, whereas all swabs taken from the unvaccinated birds yielded M. gallisepticum.
The interpretation of these results is probably that F strain in the respiratory tract of the vaccinated birds had declined to undetectable levels by ten weeks after vaccination. However, the birds were immune and resisted infection when challenged, whereas the susceptible unvaccinated birds could not. F strain vaccinated chickens had an ID 50 that was 10 3.8 higher than that of unvaccinated chickens, and a lesser number of the challenge M. gallisepticum strain colonising their tracheas (20) . F strain afforded a greater degree of protection against infection than was obtained using a bacterin (100) or with the mild strains ts-11 or 6/85 (66) . Field studies have confirmed that continuous vaccination of replacement pullets with F strain over two or more years does result in the displacement of the original field strain (64), at least as the dominant strain, if not completely. However, it would appear that, although F strain has the potential to displace endemic strains, it is also able to maintain itself in multiple-age flocks after vaccination is discontinued (S.H. Kleven, personal communication). This has prompted Kleven and co-workers to evaluate whether a poorly infectious strain, such as ts-11, may be capable of preventing infection with F strain, and thus provide the final weapon to prevent the recycling of M. gallisepticum on multiple-age flock sites (102) . The ts-11 strain has been used in Australia to eradicate wild-type M. gallisepticum from a multiple-age breeder farm complex (R. Jenner, personal communication).
Mycoplasma synoviae vaccines
While the economic effect of M. synoviae on the layer industry (81) is probably insufficient to warrant the use of vaccination, there is a need for an effective vaccine to control M. synoviae in some breeder flocks where other attempts at control have failed (94) .
Essential characteristics of MS-H vaccine strain
The MS-H strain readily colonises the respiratory tract of the chicken after eye drop administration, persisting for at least 55 weeks after vaccination and stimulating a measurable serum antibody response (80, 83) . Strain MS-H caused no lesions when inoculated into the air sacs of chickens at up to 10 times the recommended dose (K.G. Whithear and K.E. Harrigan, unpublished findings), or when administered by aerosol in combination with intratracheal inoculation of T strain IBV (83) . In both cases, the parent strain caused air sac lesions in > 80% of chickens (83; K.G. Whithear and K.E. Harrigan, unpublished findings). Strain MS-H retained a ts + phenotype and lack of virulence following five passages through chickens (including an intermediate in vitro culture step at each passage). MS-H could be administered by eye drop without obvious ill effects in combination with M. gallisepticum ts-11, or IBV or ILTV vaccines (80) . Transmission occurred to birds which came into contact with vaccinated chickens (83) .
Chickens vaccinated by eye drop with strain MS-H had a 20% incidence of air sac lesions after challenge with simultaneous aerosol administration of virulent M. synoviae and intra-tracheal inoculation of T strain IBV (83) . This was significantly less (P < 0.05) than the incidence of lesions in an unvaccinated group challenged in the same way (83) .
Field trials involving 90,000 birds were conducted in broiler breeder operations which were having particular problems with M. synoviae infection. MS-H strain persisted in the vaccinated flocks for at least 55 weeks and no wild-type M. synoviae was ever isolated from a vaccinated flock (80) . The success of MS-H vaccination depended on the birds being free from exposure to wild-type M. synoviae at the time of vaccination, however (94) . Unvaccinated (control) broiler breeders under natural exposure conditions became culture-positive for wild-type M. synoviae. No untoward clinical signs were noted in vaccinated broiler breeders and no egg transmission was detected following the culture of over 300 pipped embryos (80) . Flock data concerning vaccinated broiler breeders revealed significant improvements in their performance, and their progeny experienced no clinical disease referable to M. synoviae and remained serologically negative up to 55 days after hatching (J. Markham and P.C. Scott, personal communication).
Differentiation of vaccine strains
A number of DNA analysis techniques, including restriction endonuclease analysis (62, 85) , hybridisation probes (62) and polymerase chain reaction (PCR) (86, 87) can be used to distinguish vaccine strains from one another and from wild types. A further refinement of PCR, random amplified polymorphic DNA analysis, was used to distinguish among ts-11 and 6/85 strain (72) and F strain, ts-11 and 6/85 strains (29).
It
has not yet proved possible to distinguish the ts-11 strain from its parent (strain 80083) using DNA analysis techniques (K.G. Whithear, unpublished findings). However, fortunately strains sharing the same DNA restriction polymorphism pattern as ts-11 and 80083 are uncommon, so it is possible, with a reasonable degree of confidence, to ascertain whether a strain is of vaccine origin or not (K.G. Whithear, unpublished findings). Using restriction endonuclease analysis of PCR products from 87 strains of M. gallisepticum, it was found that strain ts-11 was confined to flocks of known vaccination history, and that the organism persisted for up to 13 months after vaccination (P. Markham, personal communication) . DNA analysis has also revealed F strain to be epidemiologically unique (43, 44, 62, 64, 87) .
A role for live vaccines in broiler breeders
Whithear and Browning argued the case for vaccination of breeder flocks in situations where there is an identifiable risk of introduction of infection (112) . Both M. gallisepticum strain ts-11 and M. synoviae strain MS-H have been used extensively in recent years for this purpose within Australia. Results have been most encouraging. In one operation involving approximately 100 million broilers per annum, problems with M. gallisepticum and M. synoviae have been dramatically reduced since the introduction of vaccination (P.C. Scott, personal communication). There have also been improved performances and reduced medication costs in breeder flocks, including a dramatic reduction in the incidence of clinical fowl cholera since the advent of mycoplasma vaccination (P.C. Scott, personal communication).
DETECTING THE IMMUNE RESPONSE TO VACCINATION
While there is a lack of association between levels of circulating antibody and protection against M. gallisepticum, serology is still commonly used to determine whether a vaccine has elicited an immune response. More importantly, serology is also used to establish that a flock has not been infected prior to vaccination. The procedures used are the same as those used in diagnosis, and include rapid serum agglutination, haemagglutination inhibition (HI) and enzyme-linked immunosorbent assay (ELISA) (59) . While detection of antibodies in tracheal washings may give a more accurate indication of protective immunity, this technique is presently used only in experimental studies.
Vaccination with bacterin stimulated a strong agglutinin and HI response (100). However, the antibody response declines with time and by 18 weeks after a single dose of oil emulsion bacterin given at three weeks of age, HI titres had declined to insignificant levels (36) . In a comparative study, F strain and an oil emulsion bacterin produced a strong serum agglutination response which persisted over a 12-week study period (1). Strain ts-11 produced a weaker response and strain 6/85 gave virtually no agglutinin response (1). Strain ts-11 normally produces a detectable serum antibody response but the intensity can vary and is sometimes weak (K.G. Whithear, unpublished findings). A lack of detectable serum antibody seems to be a feature following vaccination with the 6/85 strain (25, 72) .
FUTURE DIRECTIONS
Modern molecular and genetic techniques offer exciting new possibilities for a future generation of avian mycoplasma vaccines. Whithear and Browning (112) summarised the features of ts-11 and predicted that this strain had potential as a vector for other respiratory pathogens of poultry, such as IBV. A multicomponent vaccine based on ts-11 as a vector may simplify vaccine administration against a range of respiratory pathogens, and provide enhanced longterm immunity (112) .
One of the disadvantages of currently available vaccines is that there is no convenient serological technique to distinguish precisely between vaccinated or naturally infected flocks (112) . Specifically deleting a gene in the vaccine strain and developing a serological test based on the deleted antigen could allow this distinction to be made. Only animals exposed to the wild-type pathogen would develop antibody to the antigen. This approach to a genetic marker for a vaccine strain was first adopted widely in vaccines for Aujeszky's disease (Pseudorabies) (115) . Ideally, of course, the deleted gene might also be the gene determining virulence. A possible alternative is to develop a specifically targeted subunit vaccine. The advent of novel adjuvants such as ISCOM may enhance the efficacy of subunit vaccines.
Introducing DNA from a pathogen into host cells is a novel approach to vaccination which has shown promise in several disease models, including one for a mycoplasma (13 
